Takeda posts surprise profit a year after Shire mega-merger

Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done. 

Takeda to sell European OTC business to cut debts

Japan’s Takeda has said it would sell up to $670 million of over-the-counter (OTC) drug operations in Europe to cut its debts.

Breadth versus depth in R&D management

Takeda’s Georgia Keresty is one of the only chief operating officers (COOs) for R&D in the industry.

Plasma firms join forces on “unbranded” coronavirus treatmen...

Takeda signs $882m rare disease alliance with Oxford biotech...

Takeda's Ninlaro falls short in first line multiple myeloma

Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.